Pregnancy: Teratogenic Effects: There are no adequate and well-controlled study data in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
Lactation: Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery.
Verapamil hydrochloride/metabolites are excreted in human milk. Limited human data from oral administration has shown that the infant relative dose of verapamil is low (0.1-1% of the mother's oral dose) and that verapamil use may be compatible with breastfeeding.
A risk to the newborns/infants cannot be excluded. Due to the potential for serious adverse reactions in nursing infants, verapamil should only be used during lactation if it is essential for the welfare of the mother.
Other Services
Country
Account